Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma

Keyphrases

• Cancer Therapy 100%
• Mouse Model 100%
• Neurofibromatosis Type 1 (NF-1) 100%
• In Vitro Tumor Models 100%
• Optic Pathway Glioma 100%
• Glioma Model 40%
• Temozolomide 40%
• Tumor Volume 40%
• Novel Therapies 40%
• Genetically Engineered Mouse Models 40%
• Tumor Cell Proliferation 40%
• Low-grade Glioma 40%
• Apoptosis 20%
• Tumor Cells 20%
• Germinal Zone 20%
• Negatively Regulate 20%
• Normal Brain 20%
• Tumor Suppressor Gene 20%
• Pharmacologic 20%
• Rapamycin 20%
• Dose Effect 20%
• Additive Effect 20%
• Progenitor Cells 20%
• Glial Cells 20%
• MEMRI 20%
• Preclinical Drug Evaluation 20%
• Human Trials 20%
• Mouse Tumor Model 20%
• Gene Activation 20%
• Tumor Proliferation 20%
• No Additives 20%
• Constitutive Activation 20%
• Preclinical Trials 20%
• Neurofibromin 20%
• Mammalian Target of Rapamycin Signaling 20%
• Mammalian Target of Rapamycin Inhibition 20%
• Tumor Cell Apoptosis 20%
• Penetrance 20%
• Success Probability 20%
• Single-agent Chemotherapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Malignant Neoplasm 100%
• Mouse Model 100%
• Neurofibromatosis Type 1 100%
• Optic Nerve Glioma 100%
• Temozolomide 40%
• Glioma 40%
• Genetically Engineered Mouse Strain 40%
• Mammalian Target of Rapamycin 40%
• Clinical Trial 20%
• Tumor Growth 20%
• Rapamycin 20%
• Chemotherapy Agent 20%
• Neurofibromin 20%
• Drug Screening 20%
• Tumor Suppressor Protein 20%

Neuroscience

• Neurofibromatosis Type 1 100%
• In Vivo 40%
• Cell Proliferation 40%
• Low-Grade Glioma 40%
• Mammalian Target of Rapamycin 40%
• Temozolomide 40%
• Programmed Cell Death 40%
• Microglia 20%
• Tumor Suppressor Gene 20%
• Magnetic Resonance Imaging 20%
• Progenitor Cell 20%
• Sirolimus 20%